Multiple Sclerosis antibodies

and ELISA kits, proteins related to Multiple Sclerosis.

Introduction to Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic neurological condition that affects millions worldwide, disrupting the communication between the brain and the rest of the body. Characterized by the immune system mistakenly attacking the protective myelin sheath surrounding nerve fibers, MS leads to a wide range of physical and cognitive challenges. Symptoms can vary greatly, including fatigue, mobility issues, and impaired vision, significantly impacting daily life. Understanding the underlying mechanisms of MS is crucial for developing effective treatments. Recent advancements in antibody research offer promising avenues for targeted therapies, aiming to modulate the immune response and promote nerve repair. By exploring the role of specific antibodies in MS, scientists are paving the way toward more personalized and effective interventions, offering hope for improved quality of life for those affected by this complex disease.

Multiple Sclerosis biomarkers

PA1239

Anti-GFAP Antibody Picoband®, BSHX decoction reduced reactive astrocytosis after SCI. A Immunofluorescence images showed the reactive astrocytosis (GFAP, red) at day 3 and 7 after SCI. B Immuno...

PA1050

Anti-Myelin Basic Protein/MBP Antibody Picoband®, IF analysis of MBP using anti-MBP antibody (PA1050).
MBP was detected in a paraffin-embedded section of mouse brain tissu...

MA1045

Anti-GFAP Antibody (Monoclonal, G-A-5), Effects of MSCs treatment on the phenotype distribution of microglia and astrocytes. (A–D) Double immunofluorescence staining of Iba-1/iNOS-posi...

Protein Name	Gene Name	Function
Neurofilament light chain	NEFL	Marker of axonal damage
Glial fibrillary acidic protein	GFAP	Indicator of astroglial activation
Myelin basic protein	MBP	Component of myelin sheath; integrity marker
Immunoglobulin G (Oligoclonal Bands)	IGHG	Intrathecal antibody production
Myelin oligodendrocyte glycoprotein	MOG	Component of myelin sheath
C-reactive protein	CRP	Systemic inflammation marker
Interleukin-6	IL6	Proinflammatory cytokine
Tumor necrosis factor-alpha	TNF	Proinflammatory cytokine
CXCL13	CXCL13	B-cell chemoattractant
B-cell activating factor	TNFSF13B	B-cell proliferation and survival
CXCL10	CXCL10	T-cell chemoattractant
Chitinase-3-like protein 1	CHI3L1	Involved in inflammation and tissue remodeling
Osteopontin	SPP1	Participates in inflammatory processes
S100 calcium-binding protein B	S100B	Indicator of astrocyte activation
Matrix metalloproteinase-9	MMP9	Involved in blood-brain barrier disruption
Matrix metalloproteinase-2	MMP2	Involved in extracellular matrix degradation
HLA-DRB1	HLA-DRB1	Genetic susceptibility factor
Vitamin D receptor	VDR	Regulates immune responses
CD69	CD69	Early T-cell activation marker
CD26	DPP4	Immune modulation

Important Mechanisms

Immunological Mechanisms

Multiple Sclerosis (MS) is widely recognized as an autoimmune disorder in which the immune system erroneously targets the central nervous system (CNS). One of the most critical sub-research areas within MS is the study of immunological mechanisms. This area focuses on understanding how autoreactive T cells, B cells, and other immune components contribute to the inflammation and demyelination characteristic of MS. Researchers delve into the roles of various cytokines, chemokines, and immune cell interactions that facilitate the breach of the blood-brain barrier, allowing immune cells to infiltrate the CNS. Additionally, the interplay between the adaptive and innate immune systems is scrutinized to identify potential therapeutic targets. Advances in this field have led to the development of immunomodulatory therapies that aim to reduce disease activity by dampening specific immune responses. Understanding the intricate immunological pathways involved in MS not only aids in the identification of biomarkers for disease progression but also paves the way for personalized treatment approaches, ultimately improving patient outcomes.

Neurodegeneration and Axonal Damage

Beyond the immune-mediated aspects, neurodegeneration represents a pivotal mechanism in the progression of Multiple Sclerosis. This sub-research area investigates the processes leading to axonal damage, neuronal loss, and brain atrophy, which are closely associated with the irreversible disability seen in MS patients. Studies focus on the cellular and molecular pathways that contribute to neurodegeneration, including mitochondrial dysfunction, oxidative stress, impaired axonal transport, and excitotoxicity. Additionally, the role of glial cells, such as microglia and astrocytes, in exacerbating or mitigating neuronal injury is a key area of exploration. Understanding the mechanisms of axonal damage is crucial for developing neuroprotective strategies aimed at preserving neuronal integrity and function. Current research is exploring potential therapeutic agents that can halt or reverse neurodegenerative processes, thereby addressing the long-term disability that often accompanies MS. By targeting both the immune and neurodegenerative components of the disease, a more comprehensive approach to treatment can be achieved, offering hope for better management of MS in the future.